Achillion Pharmaceuticals, Inc.
300 George Street
New Haven
Connecticut
06511
United States
Tel: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com/
254 articles about Achillion Pharmaceuticals, Inc.
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
12/9/2019
Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020
-
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor– Phase 3 PNH initiation planned early 2020 –
11/19/2019
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the European Medicines Agency (EMA) has granted access to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who are not adequately responding to a C5 inhibitor.
-
Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
11/11/2019
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor.
-
Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/7/2019
Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020
-
Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting
11/6/2019
Achillion Pharmaceuticals, Inc. announced the acceptance of two abstracts about danicopan, the Company’s lead oral factor D inhibitor, for poster presentation at the 61st American Society of Hematology Annual Meeting to be held in Orlando, Florida from December 7-10, 2019.
-
Alexion to Acquire Achillion
10/16/2019
Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for Factor D inhibition in additional alternative pathway complement-mediated rare diseases
-
The deal is expected to close in the first half of 2020.
-
Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers
7/22/2019
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
Achillion Appoints Brian Di Donato as Chief Financial Officer
2/11/2019
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
Movers and Shakers for Sept. 17
9/17/2018
Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week. -
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
-
Achillion Initiates Phase I First-in Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
12/20/2017
This initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-5228 administered to healthy volunteers.
-
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
12/18/2017
This designation may provide, under specified conditions, for a seven-year marketing exclusivity period, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
-
Achillion Announces Pricing of Secondary Offering Of Common Stock
11/16/2017
The offering is expected to close on November 20, 2017, subject to the satisfaction of customary closing conditions.
-
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
11/15/2017
Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471.
-
Achillion Announces Proposed Secondary Offering of Common Stock
11/15/2017
Achillion will not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock will not change as a result of the offering.
-
The EMA Committee for Orphan Medicinal Products also issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.